IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second
IceCure Medical's cryoablation treatment for breast cancer got approval and good long-term results, showing doctors are increasingly using it as a gentler option. When a medical company shares positive research and expert support like this, it suggests the treatment is gaining trust—something worth watching to see if it helps the company grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.